Outcome of AL amyloidosis treated with a selection of common upfront regimens, according to disease severity
| Treatment . | Disease severity . | Patients . | HR (CR, VGPR) . | OR . | Survival . |
|---|---|---|---|---|---|
| ASCT57 | Transplant eligible | 1536 | After 2007 71% (37%, —) | After 2007, kidney, 32% | 68% at 5 y |
| ASCT61 | Transplant eligible | 629 | — (35%, —) | — | Median, 7.6 y |
| MDex63 | Treated with full-dose dexamethasone (stage IIIb 10%) | 119 | 76% (31%, 29%) | Heart, 37%; kidney, 24% | Median, 7.3 y |
| Treated with low-dose dexamethasone (stage IIIb 36%) | 140 | 51% (12%, 20%) | Heart, 20%; kidney, 17% | Median, 1.7 y (median, 7 mo in stage IIIb) | |
| CTD70 | Stage IIIb 22% | 69 | 72% (19%, 16%) | Heart, 19%; kidney, 39% | >50% at 5 y (median, 4 mo in stage IIIb) |
| BMDex71 | Stage IIIb 22% | 87 | 69% (42%, 13%) | Heart, 16%; kidney, 16% | 53% at 5 y |
| CyBorD73 | Stage I | 30 | 77% (33%, 23%) | Heart, 22% | 100% at 5 y |
| Stages II and IIIa | 128 | 67% (21%, 27%) | Heart, 4% | 50% at 5 y | |
| Stage IIIb | 43 | 42% (14%, 9%) | Overall renal response, 25% | 20% at 5 y; median, 7 mo (overall, 55% at 5 y) |
| Treatment . | Disease severity . | Patients . | HR (CR, VGPR) . | OR . | Survival . |
|---|---|---|---|---|---|
| ASCT57 | Transplant eligible | 1536 | After 2007 71% (37%, —) | After 2007, kidney, 32% | 68% at 5 y |
| ASCT61 | Transplant eligible | 629 | — (35%, —) | — | Median, 7.6 y |
| MDex63 | Treated with full-dose dexamethasone (stage IIIb 10%) | 119 | 76% (31%, 29%) | Heart, 37%; kidney, 24% | Median, 7.3 y |
| Treated with low-dose dexamethasone (stage IIIb 36%) | 140 | 51% (12%, 20%) | Heart, 20%; kidney, 17% | Median, 1.7 y (median, 7 mo in stage IIIb) | |
| CTD70 | Stage IIIb 22% | 69 | 72% (19%, 16%) | Heart, 19%; kidney, 39% | >50% at 5 y (median, 4 mo in stage IIIb) |
| BMDex71 | Stage IIIb 22% | 87 | 69% (42%, 13%) | Heart, 16%; kidney, 16% | 53% at 5 y |
| CyBorD73 | Stage I | 30 | 77% (33%, 23%) | Heart, 22% | 100% at 5 y |
| Stages II and IIIa | 128 | 67% (21%, 27%) | Heart, 4% | 50% at 5 y | |
| Stage IIIb | 43 | 42% (14%, 9%) | Overall renal response, 25% | 20% at 5 y; median, 7 mo (overall, 55% at 5 y) |
Larger and more recent studies were selected. Intent-to-treat responses are reported.
CR, complete response; HR, hematologic response; OR, organ response; VGPR, very good partial response; —, not available.